Biological treatments: New weapons in the management of monogenic autoinflammatory disorders

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Vitale, Antonio ^a   Rigante, Donato ^b   Lucherini, Orso Maria ^a   Caso, Francesco ^c   Muscari, Isabella ^a   Magnotti, Flora ^a   Brizi, Maria Giuseppina ^a   Guerrini, Susanna ^a   Patti, Maria ^b   Punzi, Leonardo ^c   Galeazzi, Mauro ^a   Cantarini, Luca ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; CANAKINUMAB; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SALAZOSULFAPYRIDINE; THALIDOMIDE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL PRODUCT; INTERLEUKIN 1 RECEPTOR; NLRP12 PROTEIN, HUMAN; SIGNAL PEPTIDE;

AMYLOIDOSIS; ARTHRALGIA; AUTOINFLAMMATORY DISEASE; BLAU SYNDROME; CINCA SYNDROME; COHORT ANALYSIS; COMPARATIVE STUDY; DEFICIENCY OF INTERLEUKIN 1 RECEPTOR ANTAGONIST; DIARRHEA; DISEASE CLASSIFICATION; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; HEADACHE; HUMAN; HYPERTENSION; INJECTION SITE REACTION; INNATE IMMUNITY; MAJEED SYNDROME; MENINGITIS; MEVALONATE KINASE DEFICIENCY; MIXED INFECTION; MONOGENIC DISORDER; MUCKLE WELLS SYNDROME; NLRP12 ASSOCIATED AUTOINFLAMMATORY DISORDER; PAPA SYNDROME; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEINURIA; REVIEW; SINUSITIS; SPINAL CORD DISEASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; UPPER RESPIRATORY TRACT INFECTION; ACNE VULGARIS; CONGENITAL DYSERYTHROPOIETIC ANEMIA; CRANIAL NEUROPATHY; HEREDITARY PERIODIC FEVER; INFECTIOUS ARTHRITIS; INFLAMMATION; METABOLISM; MUTATION; OSTEOMYELITIS; PYODERMA GANGRENOSUM; SYNOVITIS; T LYMPHOCYTE; TREATMENT OUTCOME; UVEITIS; ANEMIA, DYSERYTHROPOIETIC, CONGENITAL; ARTHRITIS, INFECTIOUS; CRANIAL NERVE DISEASES; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; HEREDITARY AUTOINFLAMMATORY DISEASES;

ACNE VULGARIS; ANEMIA, DYSERYTHROPOIETIC, CONGENITAL; ARTHRITIS, INFECTIOUS; BIOLOGICAL PRODUCTS; CRANIAL NERVE DISEASES; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; FAMILIAL MEDITERRANEAN FEVER; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEVALONATE KINASE DEFICIENCY; MUTATION; OSTEOMYELITIS; PYODERMA GANGRENOSUM; RECEPTORS, INTERLEUKIN-1; SYNOVITIS; T-LYMPHOCYTES; TREATMENT OUTCOME; UVEITIS;

EID: 84881453312     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/939847     Document Type: Review

References (164)

1. Rigante D., The fresco of autoinflammatory diseases from the pediatric perspective. Autoimmunity Reviews 2012 11 5 348 356 2-s2.0-84857500409 10.1016/j.autrev.2011.10.008
2. Sayarlioglu M., Cefle A., Inanc M., Kamali S., Dalkilic E., Gul A., Ocal L., Aral O., Konice M., Characteristics of patients with adult-onset familial Mediterranean fever in Turkey: analysis of 401 cases. International Journal of Clinical Practice 2005 59 2 202 205 2-s2.0-14744296180 10.1111/j.1742-1241.2004. 00294.x (Pubitemid 40331221)
3. Livneh A., Langevitz P., Zemer D., Zaks N., Kees S., Lidar T., Migdal A., Padeh S., Pras M., Criteria for the diagnosis of familial Mediterranean fever. Arthritis & Rheumatism 1997 40 10 1879 1885 2-s2.0-0030783102 10.1002/art.1780401023 (Pubitemid 27452541)
4. Dodé C., André M., Bienvenu T., French Hereditary Recurrent Inflammatory Disorder Study Group. The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis & Rheumatism 2002 46 2181 2188 10.1002/art.10429
5. Cantarini L., Lucherini O. M., Frediani B., Brizi M. G., Bartolomei B., Cimaz R., Galeazzi M., Rigante D., Bridging the gap between the clinician and the patient with cryopyrin-associated periodic syndromes. International Journal of Immunopathology and Pharmacology 2011 24 4 827 836 2-s2.0-84856571891
6. Lepore L., Paloni G., Caorsi R., Alessio M., Rigante D., Ruperto N., Cattalini M., Tommasini A., Zulian F., Ventura A., Martini A., Gattorno M., Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. Journal of Pediatrics 2010 157 2 310 315 2-s2.0-77955291693 10.1016/j.jpeds.2010.02.040
7. Frenkel J., Houten S. M., Waterham H. R., Wanders R. J. A., Rijkers G. T., Duran M., Kuijpers T. W., Van Luijk W., Poll-The B. T., Kuis W., Clinical and molecular variability in childhood periodic fever with hyperimmunoglobulinaemia D. Rheumatology 2001 40 5 579 584 2-s2.0-0034987162
8. Jéru I., Le Borgne G., Cochet E., Hayrapetyan H., Duquesnoy P., Grateau G., Morali A., Sarkisian T., Amselem S., Identification and functional consequences of a recurrent NLRP12 missense mutation in periodic fever syndromes. Arthritis & Rheumatism 2011 63 5 1459 1464 2-s2.0-79955566751 10.1002/art.30241
9. Sfriso P., Caso F., Tognon S., Galozzi P., Gava A., Punzi L., Blau syndrome, clinical and genetic aspects. Autoimmunity Reviews 2012 12 44 51 10.1016/j.autrev.2012.07.028
10. Ferguson P. J., Chen S., Tayeh M. K., Ochoa L., Leal S. M., Pelet A., Munnich A., Lyonnet S., Majeed H. A., El-Shanti H., Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). Journal of Medical Genetics 2005 42 7 551 557 2-s2.0-22244469461 10.1136/jmg.2005.030759 (Pubitemid 40993830)
11. Tallon B., Corkill M., Peculiarities of PAPA syndrome. Rheumatology 2006 45 9 1140 1143 2-s2.0-33749621794 10.1093/rheumatology/kei178 (Pubitemid 44542104)
12. Aksentijevich I., Masters S. L., Ferguson P. J., Dancey P., Frenkel J., Van Royen-Kerkhoff A., Laxer R., Tedgård U., Cowen E. W., Pham T.-H., Booty M., Estes J. D., Sandler N. G., Plass N., Stone D. L., Turner M. L., Hill S., Butman J. A., Schneider R., Babyn P., El-Shanti H. I., Pope E., Barron K., Bing X., Laurence A., Lee C.-C. R., Chapelle D., Clarke G. I., Ohson K., Nicholson M., Gadina M., Yang B., Korman B. D., Gregersen P. K., Van Martin Hagen P., Hak A. E., Huizing M., Rahman P., Douek D. C., Remmers E. F., Kastner D. L., Goldbach-Mansky R., An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. New England Journal of Medicine 2009 360 23 2426 2437 2-s2.0-66649121678 10.1056/NEJMoa0807865
13. Cantarini L., Lucherini O. M., Iacoponi F., Cimaz R., Simonini G., Rigante D., Laghi Pasini F., Baldari C. T., Capecchi P. L., Brizi M. G., Galeazzi M., Development and preliminary validation of a diagnostic score for identifying patients affected with adult-onset autoinflammatory disorders. International Journal of Immunopathology and Pharmacology 2010 23 4 1133 1141 2-s2.0-79953000253
14. Cantarini L., Iacoponi F., Lucherini O. M., Obici L., Brizi M. G., Cimaz R., Rigante D., Benucci M., Sebastiani G. D., Brucato A., Sabadini L., Simonini G., Giani T., Laghi Pasini F., Baldari C. T., Bellisai F., Valentini G., Bombardieri S., Paolazzi G., Galeazzi M., Validation of a diagnostic score for the diagnosis of autoinflammatory diseases in adults. International Journal of Immunopathology and Pharmacology 2011 24 3 695 702 2-s2.0-80055113996
15. Muscari I., Iacoponi F., Cantarini L., The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: our experience and review of the literature. Autoimmunity Reviews 2012 12 1 10 13 10.1016/j.autrev.2012.07.015
16. Cantarini L., Lucherini O. M., Brucato A., Barone L., Cumetti D., Iacoponi F., Rigante D., Brambilla G., Penco S., Brizi M. G., Patrosso M. C., Valesini G., Frediani B., Galeazzi M., Cimaz R., Paolazzi G., Vitale A., Imazio M., Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clinical Research in Cardiology 2012 101 525 531 2-s2.0-84856424402 10.1007/s00392-012-0422-8
17. Cantarini L., Rigante D., Brizi M. G., Clinical and biochemical landmarks in systemic autoinflammatory diseases. Annals of Medicine 2012 44 664 673 10.3109/07853890.2011.598546
18. Rigante D., The protean visage of systemic autoinflammatory syndromes: a challenge for inter-professional collaboration. European Review for Medical and Pharmacological Sciences 2010 14 1 1 18 2-s2.0-76749139472
19. Trost S., Rosé C. D., Myocarditis and sacroiliitis: 2 previously unrecognized manifestations of tumor necrosis factor receptor associated periodic syndrome. Journal of Rheumatology 2005 32 1 175 177 2-s2.0-11844294692 (Pubitemid 40092609)
20. Cantarini L., Lucherini O. M., Cimaz R., Baldari C. T., Bellisai F., Rossi Paccani S., Laghi Pasini F., Capecchi P. L., Sebastiani G. D., Galeazzi M., Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome. International Journal of Immunopathology and Pharmacology 2009 22 4 1051 1058 2-s2.0-76349123818
21. Cantarini L., Lucherini O. M., Baldari C. T., Laghi Pasini F., Galeazzi M., Familial clustering of recurrent pericarditis may disclose tumour necrosis factor receptor-associated periodic syndrome. Clinical and Experimental Rheumatology 2010 28 3 405 407 2-s2.0-77956989287
22. Vitale A., Lucherini O. M., Galeazzi M., Frediani B., Cantarini L., Long-term clinical course of patients carrying the Q703K mutation in the NLRP3 gene: a case series. Clinical and Experimental Rheumatology 2012 30 943 946
23. Cantarini L., Imazio M., Brucato A., Lucherini O. M., Galeazzi M., Innate versus acquired immune response in the pathogenesis of recurrent idiopathic pericarditis. Autoimmunity Reviews 2010 9 6 436 440 2-s2.0-77949918479 10.1016/j.autrev.2009.11.021
24. Cantarini L., Lucherini O. M., Cimaz R., Baldari C. T., Laghi Pasini F., Galeazzi M., Sacroileitis and pericarditis: atypical presentation of tumour necrosis factor receptor-associated periodic syndrome and response to etanercept therapy. Clinical and Experimental Rheumatology 2010 28 2 290 291 2-s2.0-77952754400
25. Cantarini L., Lucherini O. M., Cimaz R., Galeazzi M., Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. Clinical and Experimental Rheumatology 2010 28 5, article 802 2-s2.0-78650552920
26. McDermott M. F., Aksentijevich I., The autoinflammatory syndromes. Current Opinion in Allergy and Clinical Immunology 2002 2 511 516 10.1097/00130832-200212000-00006 (Pubitemid 36105814)
27. Stankovic K., Grateau G., Auto inflammatory syndromes: diagnosis and treatment. Joint Bone Spine 2007 74 6 544 550 2-s2.0-37049014725 10.1016/j.jbspin.2007.07.005 (Pubitemid 350245628)
28. Rigante D., Capoluongo E., The plodding diagnosis of monogenic autoinflammatory diseases in childhood: from the clinical scenery to laboratory investigation. Clinical Chemistry and Laboratory Medicine 2011 49 5 783 791 2-s2.0-79954513203 10.1515/CCLM.2011.127
29. Hoffmann G. F., Charpentier C., Mayatepek E., Mancini J., Leichsenring M., Gibson K. M., Divry P., Hrebicek M., Lehnert W., Sartor K., Trefz F. K., Rating D., Bremer H. J., Nyhan W. L., Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 1993 91 5 I 915 921 2-s2.0-0027529504 (Pubitemid 23120719)
30. Cerquaglia C., Diaco M., Nucera G., La Regina M., Montalto M., Manna R., Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Current Drug Targets: Inflammation and Allergy 2005 4 1 117 124 2-s2.0-17844377905 10.2174/1568010053622984 (Pubitemid 40584862)
31. Rigante D., La Torraca I., Avallone L., Pugliese A. L., Gaspari S., Stabile A., The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever. European Review for Medical and Pharmacological Sciences 2006 10 4 173 178 2-s2.0-33748574940 (Pubitemid 44468941)
32. Obici L., Merlini G., Amyloidosis in autoinflammatory syndromes. Autoimmunity Reviews 2012 12 14 17 10.1016/j.autrev.2012.07.016
33. Savic S., Dickie L. J., Wittmann M., McDermott M. F., Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives. Best Practice & Research Clinical Rheumatology 2012 26 4 505 533 10.1016/j.berh.2012.07.009
34. ter Haar N., Lachmann H., Ozen S., Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Annals of the Rheumatic Diseases 2013 72 5 678 685 1136/annrheumdis-2011-201268
35. Goldfinger S. E., Colchicine for familial Mediterranean fever. New England Journal of Medicine 1972 287 25 1302 2-s2.0-0015519154
36. Bakkaloglu A., Familial Mediterranean fever. Pediatric Nephrology 2003 18 9 853 859 2-s2.0-0141523268 10.1007/s00467-003-1185-2 (Pubitemid 37121615)
37. Aybal Kutlugun A., Yildirim T., Altindal M., Arici M., Yasavul Ü., Turgan Ç., AA type renal amyloidosis secondary to FMF: a long-term follow-up in two patients. Renal Failure 2010 32 10 1230 1232 2-s2.0-77958163786 10.3109/0886022X.2010.517344
38. Ozkaya N., Yalcinkaya F., Colchicine treatment in children with familial Mediterranean fever. Clinical Rheumatology 2003 22 314 317 10.1007/s10067-003- 0739-9 (Pubitemid 37483627)
39. Zemer D., Pras M., Sohar E., Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. New England Journal of Medicine 1986 314 16 1001 1005 2-s2.0-0022570984 (Pubitemid 16138694)
40. Twig G., Livneh A., Vivante A., Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents. Annals of the Rheumatic Diseases. In press
41. Erken E., Ozer H. T. E., Bozkurt B., Gunesacar R., Erken E. G., Dinkci S., Early suppression of familial Mediterranean fever attacks by single medium dose methyl-prednisolone infusion. Joint Bone Spine 2008 75 3 370 372 2-s2.0-42749097593 10.1016/j.jbspin.2007.10.004
42. Langevitz P., Zemer D., Livneh A., Protracted febrile myalgia in patients with familial mediterranean fever. Journal of Rheumatology 1994 21 9 1708 1709 2-s2.0-0028101194 (Pubitemid 24285488)
43. Seyahi E., Ozdogan H., Celik S., Ugurlu S., Yazici H., Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clinical and Experimental Rheumatology 2006 24 5 S99 S103 2-s2.0-33750738072 (Pubitemid 44696888)
44. Ozgocmen S., Özçakar L., Ardicoglu O., Kocakoc E., Kaya A., Kiris A., Familial Mediterranean fever responds well to infliximab: single case experience. Clinical Rheumatology 2006 25 1 83 87 2-s2.0-33645733454 10.1007/s10067-005-1122-9
45. Nakamura A., Matsuda M., Tazawa K.-I., Shimojima Y., Ikeda S.-I., Successful treatment with infliximab and low-dose methotrexate in a Japanese patient with familial Mediterranean fever. Internal Medicine 2007 46 15 1247 1249 2-s2.0-34548075550 10.2169/internalmedicine.46.0064 (Pubitemid 47354446)
46. Mor A., Pillinger M. H., Kishimoto M., Abeles A. M., Livneh A., Familial mediterranean fever successfully treated with etanercept. Journal of Clinical Rheumatology 2007 13 1 38 40 2-s2.0-33846846354 10.1097/01.rhu.0000255772.25658. 7c (Pubitemid 46213843)
47. Metyas S., Arkfeld D. G., Forrester D. M., Ehresmann G. R., Infliximab treatment of familial Mediterranean fever and its effect on secondary AA amyloidosis. Journal of Clinical Rheumatology 2004 10 3 134 137 2-s2.0-3042592556 10.1097/01.rhu.0000128856.13595.eb (Pubitemid 38821988)
48. Bodur H., Seçkin U., Eser F., Ergül G., Seçkin S., Coexistence of familial Mediterranean fever and psoriasis in a patient with seronegative spondyloarthropathy. Rheumatology International 2008 29 107 110 10.1007/s00296-008-0616-6
49. Erten S., Erten S. F., Altunoglu A., Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF. Rheumatology International 2011 32 1095 1097 2-s2.0-79952720977 10.1007/s00296-011-1855-5
50. Ozgocmen S., Akgul O., Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature. Modern Rheumatology 2011 21 6 684 690 2-s2.0-84855658573 10.1007/s10165-011-0463-2
51. Özçakar Z. B., Yüksel S., Ekim M., Yalçnkaya F., Infliximab therapy for familial Mediterranean fever-related amyloidosis: case series with long term follow-up. Clinical Rheumatology 2012 31 1267 1271
52. Takahashi T., Tsukuda H., Itoh H., Kimura H., Yoshimoto M., Tsujisaki M., An atypical familial Mediterranean fever patient who developed ulcers in the terminal ileum and recurrent abscess-like lesions in multiple organs. Internal Medicine 2012 51 2239 2244
53. Ryan J. G., Masters S. L., Booty M. G., Habal N., Alexander J. D., Barham B. K., Remmers E. F., Barron K. S., Kastner D. L., Aksentijevich I., Clinical features and functional significance of the P369S/R408Q variant in pyrin, the familial Mediterranean fever protein. Annals of the Rheumatic Diseases 2010 69 7 1383 1388 2-s2.0-77954999821 10.1136/ard.2009.113415
54. Özen S., Bilginer Y., Ayaz N. A., Calguneri M., Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. Journal of Rheumatology 2011 38 3 516 518 2-s2.0-79952425658 10.3899/jrheum.100718
55. Cantarini L., Volpi N., Galeazzi M., Giani T., Fanti F., Lucherini O. M., Aglianò M., Alessandrini C., Giannini F., Magi S., Greco G., Baldari C. T., Cimaz R., Colchicine myopathy and neuromyopathy: two cases with different characteristics. Journal of Clinical Rheumatology 2010 16 5 229 232 2-s2.0-77955187512 10.1097/RHU.0b013e3181e96342
56. Meinzer U., Quartier P., Alexandra J.-F., Hentgen V., Retornaz F., Koné-Paut I., Interleukin-1 targeting drugs in familial mediterranean fever: a case series and a review of the literature. Seminars in Arthritis and Rheumatism 2011 41 2 265 271 2-s2.0-79955138270 10.1016/j.semarthrit.2010.11.003
57. Chae J. J., Aksentijevich I., Kastner D. L., Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. British Journal of Haematology 2009 146 5 467 478 2-s2.0-69049085064 10.1111/j.1365-2141.2009.07733.x
58. Soriano A., Verecchia E., Afeltra A., Landolfi R., Manna R., IL-1 β biological treatment of familial Mediterranean fever. Clinical Reviews in Allergy & Immunology 2013 10.1007/s12016-013-8358-y
59. Chae J. J., Wood G., Masters S. L., Richard K., Park G., Smith B. J., Kastner D. L., The B30.2 domain of pyrin, the familial mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1 β production. Proceedings of the National Academy of Sciences of the United States of America 2006 103 26 9982 9987 2-s2.0-33745631232 10.1073/pnas.0602081103 (Pubitemid 43993609)
60. Stankovic Stojanovic K., Delmas Y., Torres P. U., Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrology Dialysis Transplantation 2012 27 1898 1901 10.1093/ndt/gfr528
61. Bilginer Y., Ayaz N. A., Ozen S., Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease. Clinical Rheumatology 2010 29 2 209 210 2-s2.0-77949884645 10.1007/s10067-009-1279-8
62. Mitroulis I., Papadopoulos V. P., Konstantinidis T., Ritis K., Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. Netherlands Journal of Medicine 2008 66 11 489 491 2-s2.0-57849127198
63. Moser C., Pohl G., Haslinger I., Knapp S., Rowczenio D., Russel T., Lachmann H. J., Lang U., Kovarik J., Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrology Dialysis Transplantation 2009 24 2 676 678 2-s2.0-58449114163 10.1093/ndt/gfn646
64. Gattringer R., Lagler H., Gattringer K. B., Knapp S., Burgmann H., Winkler S., Graninger W., Thalhammer F., Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. European Journal of Clinical Investigation 2007 37 11 912 914 2-s2.0-35648986741 10.1111/j.1365-2362.2007.01868.x (Pubitemid 350029205)
65. Belkhir R., Moulonguet-Doleris L., Hachulla E., Prinseau J., Baglin A., Hanslik T., Treatment of familial mediterranean fever with anakinra. Annals of Internal Medicine 2007 146 11 825 826 2-s2.0-34250623231 (Pubitemid 351650515)
66. Alpay N., Sumnu A., Calşkan Y., Yazc H., Türkmen A., Gül A., Efficacy of anakinra treatment in a patient with colchicine resistant familial Mediterranean fever. Rheumatology International 2012 32 3277 3279 10.1007/s00296-010-1474-6
67. Mitroulis I., Skendros P., Oikonomou A., Tzioufas A. G., Ritis K., The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. Annals of the Rheumatic Diseases 2011 70 7 1347 1348 2-s2.0-79957663056 10.1136/ard.2010. 146878
68. Hacihamdioglu D. O., Ozen S., Canakinumab induces remission in a patient with resistant familial Mediterranean fever. Rheumatology 2012 51 article 1041
69. Hashkes P. J., Spalding S. J., Giannini E. H., Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Annals of Internal Medicine 2012 157 533 541 10.7326/0003-4819-157-8- 201210160-00003
70. Hull K. M., Drewe E., Aksentijevich I., Singh H. K., Wong K., McDermott E. M., Dean J., Powell R. J., Kastner D. L., The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine 2002 81 5 349 368 2-s2.0-0036733312 10.1097/00005792-200209000-00002
71. McDermott M. F., Aksentijevich I., Galon J., McDermott E. M., William Ogunkolade B., Centola M., Mansfield E., Gadina M., Karenko L., Pettersson T., McCarthy J., Frucht D. M., Aringer M., Torosyan Y., Teppo A.-M., Wilson M., Mehmet Karaarslan H., Wan Y., Todd L., Wood G., Schlimgen R., Kumarajeewa T. R., Cooper S. M., Vella J. P., Amos C. I., Mulley J., Quane K. A., Molloy M. G., Ranki A., Powell R. J., Hitman G. A., O'Shea J. J., Kastner D. L., Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999 97 1 133 144 2-s2.0-0033515520 (Pubitemid 29165896)
72. Cantarini L., Rigante D., Lucherini O. M., Cimaz R., Laghi Pasini F., Baldari C. T., Benucci M., Simonini G., Di Sabatino V., Brizi M. G., Galeazzi M., Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature. International Journal of Immunopathology and Pharmacology 2010 23 3 701 707 2-s2.0-78149272003
73. Aganna E., Hawkins P. N., Ozen S., Pettersson T., Bybee A., McKee S. A., Lachmann H. J., Karenko L., Ranki A., Bakkaloglu A., Besbas N., Topaloglu R., Hoffman H. M., Hitman G. A., Woo P., McDermott M. F., Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes and Immunity 2004 5 4 289 293 2-s2.0-3242680646 10.1038/sj.gene.6364070 (Pubitemid 38961162)
74. Nowlan M. L., Drewe E., Bulsara H., Esposito N., Robins R. A., Tighe P. J., Powell R. J., Todd I., Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology 2006 45 1 31 37 2-s2.0-29844442446 10.1093/rheumatology/kei090 (Pubitemid 43033871)
75. Stojanov S., Dejaco C., Lohse P., Huss K., Duftner C., Belohradsky B. H., Herold M., Schirmer M., Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Annals of the Rheumatic Diseases 2008 67 9 1292 1298 2-s2.0-50249188364 10.1136/ard.2007.079376
76. Aróstegui J. I., Solís P., Aldea A., Cantero T., Rius J., Bahíllo P., Plaza S., Vives J., Gómez S., Yagüe J., Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associated periodic syndrome abolishes auto-inflammatory episodes without normalising the subclinical acute phase response. European Journal of Pediatrics 2005 164 1 13 16 2-s2.0-19944429780 10.1007/s00431-004-1563-1 (Pubitemid 40110001)
77. Kusuhara K., Hoshina T., Saito M., Successful treatment of a patient with tumor necrosis factor receptor-associated periodic syndrome using a half-dose of etanercept. Pediatrics International 2012 54 552 555 10.1111/j.1442-200X. 2011.03525.x
78. Drewe E., Huggins M. L., Morgan A. G., Cassidy M. J. D., Powell R. J., Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology 2004 43 11 1405 1408 2-s2.0-8344258346 10.1093/rheumatology/keh357 (Pubitemid 39480929)
79. Bulua A. C., Mogul D. B., Aksentijevich I., Singh H., He D. Y., Muenz L. R., Ward M. M., Yarboro C. H., Kastner D. L., Siegel R. M., Hull K. M., Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis & Rheumatism 2012 64 3 908 913 2-s2.0-84857739991 10.1002/art.33416
80. Gattorno M., Pelagatti M. A., Meini A., Obici L., Barcellona R., Federici S., Buoncompagni A., Plebani A., Merlini G., Martini A., Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis & Rheumatism 2008 58 5 1516 1520 2-s2.0-43949128071 10.1002/art.23475 (Pubitemid 351705941)
81. Drewe E., Powell R. J., Mcdermott E. M., Comment on: failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology 2007 46 12 1865 1866 2-s2.0-36448947978 10.1093/rheumatology/kem231 (Pubitemid 350168311)
82. Jacobelli S., André M., Alexandra J.-F., Dodé C., Papo T., Failure of anti-TNF therapy in TNF receptor 1-associated Periodic Syndrome (TRAPS). Rheumatology 2007 46 7 1211 1212 2-s2.0-34447308222 10.1093/rheumatology/kel298 (Pubitemid 47050633)
83. Church L. D., Churchman S. M., Hawkins P. N., McDermott M. F., Hereditary auto-inflammatory disorders and biologics. Springer Seminars in Immunopathology 2006 27 4 494 508 2-s2.0-33744762863 10.1007/s00281-006-0015-6 (Pubitemid 43825168)
84. Nedjai B., Hitman G. A., Quillinan N., Coughlan R. J., Church L., McDermott M. F., Turner M. D., Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis & Rheumatism 2009 60 2 619 625 2-s2.0-59649101629 10.1002/art.24294
85. Scallon B., Cai A., Solowski N., Rosenberg A., Song X.-Y., Shealy D., Wagner C., Binding and functional comparisons of two types of tumor necrosis factor antagonists. Journal of Pharmacology and Experimental Therapeutics 2002 301 2 418 426 2-s2.0-0036229932 10.1124/jpet.301.2.418 (Pubitemid 34429950)
86. Obici L., Meini A., Cattalini M., Chicca S., Galliani M., Donadei S., Plebani A., Merlini G., Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Annals of the Rheumatic Diseases 2011 70 8 1511 1512 2-s2.0-79959793377 10.1136/ard.2010.143438
87. Quillinan N., Mannion G., Mohammad A., Coughlan R., Dickie L. J., McDermott M. F., McGonagle D., Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome. Annals of the Rheumatic Diseases 2011 70 9 1692 1693 2-s2.0-80051473290 10.1136/ard.2010.144279
88. Brizi M. G., Galeazzi M., Lucherini O. M., Cantarini L., Cimaz R., Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. Annals of Internal Medicine 2012 156 12 907 908 10.7326/0003-4819-156-12-201206190-00027
89. Gattorno M., Obici L., Meini A., Efficacy and safety of canakinumab in patients with TNF receptor associated periodic syndrome. Annals of the Rheumatic Diseases 2012 71 supplement 3, article 289
90. Vaitla P. M., Radford P. M., Tighe P. J., Powell R. J., McDermott E. M., Todd I., Drewe E., Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome. Arthritis & Rheumatism 2011 63 4 1151 1155 2-s2.0-79953689919 10.1002/art.30215
91. Leslie K. S., Lachmann H. J., Bruning E., McGrath J. A., Bybee A., Gallimore J. R., Roberts P. F., Woo P., Grattan C. E., Hawkins P. N., Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Archives of Dermatology 2006 142 12 1591 1597 2-s2.0-33845686908 10.1001/archderm.142.12. 1591 (Pubitemid 44969215)
92. Agostini L., Martinon F., Burns K., McDermott M. F., Hawkins P. N., Tschopp J., NALP3 forms an IL-1 β -processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004 20 3 319 325 2-s2.0-1642285783 10.1016/S1074-7613(04)00046-9 (Pubitemid 38388233)
93. Gattorno M., Tassi S., Carta S., Delfino L., Ferlito F., Pelagatti M. A., D'Osualdo A., Buoncompagni A., Alpigiani M. G., Alessio M., Martini A., Rubartelli A., Pattern of interleukin-1 β secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis & Rheumatism 2007 56 9 3138 3148 2-s2.0-34848875155 10.1002/art.22842 (Pubitemid 47502762)
94. Gillmore J. D., Lovat L. B., Persey M. R., Pepys M. B., Hawkins P. N., Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001 358 9275 24 29 2-s2.0-0035822274 10.1016/S0140-6736(00)05252-1 (Pubitemid 32709735)
95. Hawkins P. N., Lachmann H. J., McDermott M. F., Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. New England Journal of Medicine 2003 348 25 2583 2584 2-s2.0-0037792866 10.1056/NEJM200306193482523 (Pubitemid 36706554)
96. Hoffman H. M., Rosengren S., Boyle D. L., Cho J. Y., Nayar J., Mueller J. L., Anderson J. P., Wanderer A. A., Firestein G. S., Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. The Lancet 2004 364 9447 1779 1785 2-s2.0-8444225132 10.1016/S0140-6736(04)17401-1 (Pubitemid 39488063)
97. Ramos E., Aróstegui J. I., Campuzano S., Rius J., Bousoño C., Yagüe J., Positive clinical and biochemical responses to anakinra in a 3-yr-old patient with cryopyrin-associated periodic syndrome (CAPS). Rheumatology 2005 44 8 1072 1073 2-s2.0-24944528385 10.1093/rheumatology/keh652 (Pubitemid 41487188)
98. Rigante D., Ansuini V., Caldarelli M., Bertoni B., La Torraca I., Stabile A., Hydrocephalus in CINCA syndrome treated with anakinra. Child's Nervous System 2006 22 4 334 337 2-s2.0-33645315777 10.1007/s00381-006-1280-3
99. Boschan C., Witt O., Lohse P., Foeldvari I., Zappel H., Schweigerer L., Neonatal-onset multisystem inflammatory disease (NOMID) due to a novel S331R mutation of the CIAS1 gene and response to interleukin-1 receptor antagonist treatment. American Journal of Medical Genetics 2006 140 8 883 886 2-s2.0-33645561945 10.1002/ajmg.a.31148
100. Goldbach-Mansky R., Dailey N. J., Canna S. W., Gelabert A., Jones J., Rubin B. I., Kim H. J., Brewer C., Zalewski C., Wiggs E., Hill S., Turner M. L., Karp B. I., Aksentijevich I., Pucino F., Penzak S. R., Haverkamp M. H., Stein L., Adams B. S., Moore T. L., Fuhlbrigge R. C., Shaham B., Jarvis J. N., O'Neil K., Vehe R. K., Beitz L. O., Gardner G., Hannan W. P., Warren R. W., Horn W., Cole J. L., Paul S. M., Hawkins P. N., Tuyet H. P., Snyder C., Wesley R. A., Hoffmann S. C., Holland S. M., Butman J. A., Kastner D. L., Neonatal-onset multisystem inflammatory disease responsive to interleukin-1 β inhibition. New England Journal of Medicine 2006 355 6 581 592 2-s2.0-33746876396 10.1056/NEJMoa055137 (Pubitemid 44200651)
101. Rigante D., Leone A., Marrocco R., Laino M. E., Stabile A., Long-term response after 6-year treatment with anakinra and onset of focal bone erosion in neonatal-onset multisystem inflammatory disease (NOMID/CINCA). Rheumatology International 2011 31 12 1661 1664 2-s2.0-83555160888 10.1007/s00296-010-1787-5
102. Lachmann H. J., Lowe P., Felix S. D., Rordorf C., Leslie K., Madhoo S., Wittkowski H., Bek S., Hartmann N., Bosset S., Hawkins P. N., Jung T., In vivo regulation of interleukin 1 β in patients with cryopyrin-associated periodic syndromes. Journal of Experimental Medicine 2009 206 5 1029 1036 2-s2.0-66049094734 10.1084/jem.20082481
103. Lachmann H. J., Kone-Paut I., Kuemmerle-Deschner J. B., Leslie K. S., Hachulla E., Quartier P., Gitton X., Widmer A., Patel N., Hawkins P. N., Use of canakinumab in the cryopyrin-associated periodic syndrome. New England Journal of Medicine 2009 360 23 2416 2425 2-s2.0-66649102432 10.1056/NEJMoa0810787
104. Kuemmerle-Deschner J. B., Ramos E., Blank N., Roesler J., Felix S. D., Jung T., Stricker K., Chakraborty A., Tannenbaum S., Wright A. M., Rordorf C., Canakinumab (ACZ885, a fully human IgG1 anti-IL-1 β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Research and Therapy 2011 13 1, article R34 2-s2.0-79952053673 10.1186/ar3266
105. Kuemmerle-Deschner J. B., Hachulla E., Cartwright R., Hawkins P. N., Tran T. A., Bader-Meunier B., Hoyer J., Gattorno M., Gul A., Smith J., Leslie K. S., Jiménez S., Morell-Dubois S., Davis N., Patel N., Widmer A., Preiss R., Lachmann H. J., Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Annals of the Rheumatic Diseases 2011 70 12 2095 2102 2-s2.0-84860389457 10.1136/ard.2011.152728
106. Koné-Paut I., Lachmann H. J., Kuemmerle-Deschner J. B., Hachulla E., Leslie K. S., Mouy R., Ferreira A., Lheritier K., Patel N., Preiss R., Hawkins P. N., Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: Results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Research and Therapy 2011 13 6, article R202 2-s2.0-84855796483 10.1186/ar3535
107. Imagawa T., Nishikomori R., Takada H., Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results). Clinical and Experimental Rheumatology 2013 31 302 309
108. Goldbach-Mansky R., Shroff S. D., Wilson M., Snyder C., Plehn S., Barham B., Pham T.-H., Pucino F., Wesley R. A., Papadopoulos J. H., Weinstein S. P., Mellis S. J., Kastner D. L., A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (Interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis & Rheumatism 2008 58 8 2432 2442 2-s2.0-49449094892 10.1002/art.23620
109. Hoffman H. M., Throne M. L., Amar N. J., Sebai M., Kivitz A. J., Kavanaugh A., Weinstein S. P., Belomestnov P., Yancopoulos G. D., Stahl N., Mellis S. J., Efficacy and safety of rilonacept (Interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis & Rheumatism 2008 58 8 2443 2452 2-s2.0-49449094179 10.1002/art.23687
110. Hoffman H. M., Throne M. L., Amar N. J., Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clinical Therapeutics 2012 34 2091 2103 10.1016/j.clinthera.2012.09.009
111. Bader-Meunier B., Florkin B., Sibilia J., Acquaviva C., Hachulla E., Grateau G., Richer O., Farber C. M., Fischbach M., Hentgen V., Jego P., Laroche C., Neven B., Lequerré T., Mathian A., Pellier I., Touitou I., Rabier D., Prieur A.-M., Cuisset L., Quartier P., Mevalonate kinase deficiency: a survey of 50 patients. Pediatrics 2011 128 1 e152 e159 2-s2.0-79959933887 10.1542/peds.2010-3639
112. van der Hilst J. C. H., Bodar E. J., Barron K. S., Frenkel J., Drenth J. P. H., van der Meer J. W. M., Simon A., Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine 2008 87 6 301 310 2-s2.0-58149195381 10.1097/MD. 0b013e318190cfb7
113. Simon A., Drewe E., van der Meer J. W. M., Powell R. J., Kelley R. I., Stalenhoef A. F. H., Drenth J. P. H., Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clinical Pharmacology and Therapeutics 2004 75 5 476 483 2-s2.0-2042501706 10.1016/j.clpt.2004.01.012 (Pubitemid 38534568)
114. Drenth J. P. H., van Deuren M., van der Ven-Jongekrijg J., Schalkwijk C. G., van der Meer J. W. M., Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Blood 1995 85 12 3586 3593 2-s2.0-0029009413
115. Cailliez M., Garaix F., Rousset-Rouvière C., Bruno D., Kone-Paut I., Sarles J., Chabrol B., Tsimaratos M., Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. Journal of Inherited Metabolic Disease 2006 29 6 763 2-s2.0-33845807104
116. Neven B., Valayannopoulos V., Quartier P., Blanche S., Prieur A.-M., Debré M., Rolland M.-O., Rabier D., Cuisset L., Cavazzana-Calvo M., De Lonlay P., Fischer A., Allogeneic bone marrow transplantation in mevalonic aciduria. New England Journal of Medicine 2007 356 26 2700 2703 2-s2.0-34347233869 10.1056/NEJMoa070715 (Pubitemid 47001038)
117. Rigante D., Ansuini V., Bertoni B., Pugliese A. L., Avallone L., Federico G., Stabile A., Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatology International 2006 27 1 97 100 2-s2.0-33750489045 10.1007/s00296-006-0164-x (Pubitemid 44655757)
118. Korppi M., van Gijn M. E., Antila K., Hyperimmunoglobulinemia D and periodic fever syndrome in children. Review on therapy with biological drugs and case report. Acta Paediatrica, International Journal of Paediatrics 2011 100 1 21 25 2-s2.0-78650092436 10.1111/j.1651-2227.2010.01974.x
119. Galeotti C., Meinzer U., Quartier P., Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology (Oxford) 2012 51 1855 1859
120. Bodar E. J., Kuijk L. M., Drenth J. P. H., Van Der Meer J. W. M., Simon A., Frenkel J., On-demand anakinra treatment is effective in mevalonate kinase deficiency. Annals of the Rheumatic Diseases 2011 70 12 2155 2158 2-s2.0-84860389029 10.1136/ard.2011.149922
121. Topalolu R., Ayaz N. A., Waterham H. R., Yüce A., Gumruk F., Sanal Ö., Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-up. Clinical Rheumatology 2008 27 10 1317 1320 2-s2.0-51549087763 10.1007/s10067-008-0911-3
122. Takada K., Aksentijevich I., Mahadevan V., Dean J. A., Kelley R. I., Kastner D. L., Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis & Rheumatism 2003 48 9 2645 2651 2-s2.0-0141453408 10.1002/art.11218 (Pubitemid 37129442)
123. Kraus C. L., Culican S. M., Nummular keratopathy in a patient with Hyper-IgD Syndrome. Pediatric Rheumatology 2009 7, article 14 2-s2.0-69349102906 10.1186/1546-0096-7-14
124. Shendi H. M., Walsh D., Edgar J. D. M., Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome. Rheumatology International 2012 32 1 249 251 2-s2.0-84857115753 10.1007/s00296-009-1322-8
125. Borghini S., Tassi S., Chiesa S., Caroli F., Carta S., Caorsi R., Fiore M., Delfino L., Lasigliè D., Ferraris C., Traggiai E., Di Duca M., Santamaria G., D'Osualdo A., Tosca M., Martini A., Ceccherini I., Rubartelli A., Gattorno M., Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation. Arthritis & Rheumatism 2011 63 3 830 839 2-s2.0-79953702540 10.1002/art.30170
126. Jéru I., Duquesnoy P., Fernandes-Alnemri T., Cochet E., Yu J. W., Lackmy-Port-Lis M., Grimprel E., Landman-Parker J., Hentgen V., Marlin S., McElreavey K., Sarkisian T., Grateau G., Alnemri E. S., Amselem S., Mutations in NALP12 cause hereditary periodic fever syndromes. Proceedings of the National Academy of Sciences of the United States of America 2008 105 5 1614 1619 2-s2.0-40349113175 10.1073/pnas.0708616105 (Pubitemid 351346563)
127. Jéru I., Hentgen V., Normand S., Duquesnoy P., Cochet E., Delwail A., Grateau G., Marlin S., Amselem S., Lecron J.-C., Role of interleukin-1 β in NLRP12-associated autoinflammatory disorders and resistance to anti-interleukin-1 therapy. Arthritis & Rheumatism 2011 63 7 2142 2148 2-s2.0-79959840140 10.1002/art.30378
128. Kurokawa T., Kikuchi T., Ohta K., Imai H., Yoshimura N., Ocular manifestations in Blau syndrome associated with a CARD15/Nod2 mutation. Ophthalmology 2003 110 10 2040 2044 2-s2.0-0141747229 10.1016/S0161-6420(03) 00717-6 (Pubitemid 37163327)
129. Blau E. B., Familial granulomatous arthritis, iritis, and rash. Journal of Pediatrics 1985 107 5 689 693 2-s2.0-0022213722 (Pubitemid 16250502)
130. Punzi L., Furlan A., Podswiadek M., Gava A., Valente M., De Marchi M., Peserico A., Clinical and genetic aspects of Blau syndrome: a 25-year follow-up of one family and a literature review. Autoimmunity Reviews 2009 8 3 228 232 2-s2.0-58149474704 10.1016/j.autrev.2008.07.034
131. Latkany P. A., Jabs D. A., Smith J. R., Rosenbaum J. T., Tessler H., Schwab I. R., Walton R. C., Thorne J. E., Maguire A. M., Multifocal choroiditis in patients with familial juvenile systemic granulomatosis. American Journal of Ophthalmology 2002 134 6 897 904 2-s2.0-0036895932 10.1016/S0002-9394(02)01709-9 (Pubitemid 35425460)
132. Altschuler E. L., Kast R. E., Bupropion for Blau syndrome. Medical Hypotheses 2004 62 2 297 298 2-s2.0-1342310827 10.1016/S0306-9877(03)00334-7 (Pubitemid 38253400)
133. Milman N., Andersen C. B., Hansen A., Van Overeem Hansen T., Nielsen F. C., Fledelius H., Ahrens P., Nielsen O. H., Favourable effect of TNF- α inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation. APMIS 2006 114 12 912 919 2-s2.0-33845707639 10.1111/j.1600-0463.2006.apm-522.x (Pubitemid 44967328)
134. Raiji V. R., Miller M. M., Jung L. K., Uveitis in Blau syndrome from a de novo mutation of the NOD2/CARD15 gene. Journal of AAPOS 2011 15 2 205 207 2-s2.0-79956218796 10.1016/j.jaapos.2011.02.004
135. Martin T. M., Zhang Z., Kurz P., Rose C. D., Chen H., Lu H., Planck S. R., Davey M. P., Rosenbaum J. T., The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity. Arthritis & Rheumatism 2009 60 2 611 618 2-s2.0-59649127380 10.1002/art.24222
136. Caracseghi F., Izquierdo-Blasco J., Sanchez-Montanez A., Melendo-Perez S., Roig-Quilis M., Modesto C., Etanercept-induced myelopathy in a pediatric case of Blau syndrome. Case Reports in Rheumatology 2011 2011 5 134106 10.1155/2011/134106
137. Cuesta I. A., Moore E. C., Rabah R., Bawle E. V., Blau syndrome (familial granulomatous arthritis, iritis, and rash) in an African-American family. Journal of Clinical Rheumatology 2000 6 1 30 34 2-s2.0-0034006361 (Pubitemid 30127493)
138. Sharma S. M., Martin T. M., Rosé C. D., Dick A. D., Ramanan A. V., Distinguishing between the innate immune response due to ocular inflammation and infection in a child with juvenile systemic granulomatous disease treated with anti-TNF- α monoclonal antibodies. Rheumatology 2011 50 5 990 992 2-s2.0-79955134669 10.1093/rheumatology/keq431
139. Aróstegui J. I., Arnal C., Merino R., Modesto C., Carballo M. A., Moreno P., García-Consuegra J., Naranjo A., Ramos E., De Paz P., Rius J., Plaza S., Yagüe J., NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis & Rheumatism 2007 56 11 3805 3813 2-s2.0-36048981805 10.1002/art.22966 (Pubitemid 350100713)
140. Simonini G., Xu Z., Caputo R., Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. Arthritis & Rheumatism 2013 65 2 513 518 10.1002/art.37776
141. Yasui K., Yashiro M., Tsuge M., Manki A., Takemoto K., Yamamoto M., Morishima T., Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/blau syndrome: its possible action and mechanism. Arthritis & Rheumatism 2010 62 1 250 257 2-s2.0-74849116666 10.1002/art.25035
142. Majeed H. A., Kalaawi M., Mohanty D., Teebi A. S., Tunjekar M. F., Al-Gharbawy F., Majeed S. A., Al-Gazzar A. H., Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis in three related children and the association with Sweet syndrome in two siblings. Journal of Pediatrics 1989 115 5 730 734 2-s2.0-0024466508 (Pubitemid 19270263)
143. Majeed H. A., Al-Tarawna M., El-Shanti H., Kamel B., Al-Khalaileh F., The syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia. Report of a new family and a review. European Journal of Pediatrics 2001 160 12 705 710 2-s2.0-0035213576 (Pubitemid 33139883)
144. Majeed H. A., El-Shanti H., Al-Rimawi H., Al-Masri N., On mice and men: an autosomal recessive syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anemia. Journal of Pediatrics 2000 137 3 441 442 2-s2.0-0033831130
145. Al-Mosawi Z. S., Al-Saad K. K., Ijadi-Maghsoodi R., El-Shanti H. I., Ferguson P. J., A splice site mutation confirms the role of LPIN2 in Majeed syndrome. Arthritis & Rheumatism 2007 56 3 960 964 2-s2.0-33947137738 10.1002/art.22431 (Pubitemid 46399443)
146. Herlin T., Fiirgaard B., Bjerre M., Efficacy of anti-IL-1 treatment in Majeed syndrome. Annals of the Rheumatic Diseases 2013 72 410 413 10.1136/annrheumdis-2012-201818
147. Llndor N. M., Arsenault T. M., Solomon H., Seidman C. E., McEvov M. T., A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clinic Proceedings 1997 72 7 611 615 2-s2.0-0030804743 (Pubitemid 27330245)
148. Demidowich A. P., Freeman A. F., Kuhns D. B., Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne). Arthritis & Rheumatism 2012 64 6 2022 2027 10.1002/art.34332
149. Stichweh D. S., Punaro M., Pascual V., Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatric Dermatology 2005 22 3 262 265 2-s2.0-19644375183 10.1111/j.1525-1470.2005.22320. x (Pubitemid 40741268)
150. Cortis E., de Benedetti F., Insalaco A., Cioschi S., Muratori F., D'Urbano L. E., Ugazio A. G., Abnormal production of the tumor necrosis factor inhibitor etanercept and clinical efficacy of tumor in a patient with PAPA syndrome. Journal of Pediatrics 2004 145 6 851 855 2-s2.0-9744236591 10.1016/j.jpeds.2004.08.001 (Pubitemid 39586631)
151. Tofteland N. D., Shaver T. S., Clinical efficacy of etanercept for treatment of PAPA syndrome. Journal of Clinical Rheumatology 2010 16 5 244 245 10.1097/RHU.0b013e3181e969b9
152. Lee H., Park S. H., Kim S. K., Choe J. Y., Park J. S., Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome) with E250K mutation in CD2BP1 gene treated with the tumor necrosis factor inhibitor adalimumab. Clinical and Experimental Rheumatology 2012 30 article 452
153. Shoham N. G., Centola M., Mansfield E., Hull K. M., Wood G., Wise C. A., Kastner D. L., Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proceedings of the National Academy of Sciences of the United States of America 2003 100 23 13501 13506 2-s2.0-0344823965 10.1073/pnas.2135380100 (Pubitemid 37444771)
154. Dierselhuis M. P., Frenkel J., Wulffraat N. M., Boelens J. J., Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology 2005 44 3 406 408 2-s2.0-14944380059 10.1093/rheumatology/keh479 (Pubitemid 40361307)
155. Brenner M., Ruzicka T., Plewig G., Thomas P., Herzer P., Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. British Journal of Dermatology 2009 161 5 1199 1201 2-s2.0-71149085612 10.1111/j.1365-2133.2009.09404.x
156. Schellevis M. A., Stoffels M., Hoppenreijs E. P. A. H., Bodar E., Simon A., van der Meer J. W. M., Variable expression and treatment of PAPA syndrome. Annals of the Rheumatic Diseases 2011 70 6 1168 1170 2-s2.0-79955825388 10.1136/ard.2009.126185
157. Geusau A., Mothes-Luksch N., Nahavandi H., Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatology 2013 149 209 215 10.1001/2013. jamadermatol.717
158. Thacker P. G., Binkovitz L. A., Thomas K. B., Deficiency of interleukin-1-receptor antagonist syndrome: a rare auto-inflammatory condition that mimics multiple classic radiographic findings. Pediatric Radiology 2012 42 495 498 2-s2.0-79960565644 10.1007/s00247-011-2208-y
159. Jesus A. A., Osman M., Silva C. A., Kim P. W., Pham T.-H., Gadina M., Yang B., Bertola D. R., Carneiro-Sampaio M., Ferguson P. J., Renshaw B. R., Schooley K., Brown M., Al-Dosari A., Al-Alami J., Sims J. E., Goldbach-Mansky R., El-Shanti H., A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. Arthritis & Rheumatism 2011 63 12 4007 4017 2-s2.0-82455198846 10.1002/art.30588
160. Minkis K., Aksentijevich I., Goldbach-Mansky R., Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis. Archives of Dermatology 2012 148 747 752 10.1001/archdermatol.2011.3208
161. Stenerson M., Dufendach K., Aksentijevich I., Brady J., Austin J., Reed A. M., The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist. Arthritis & Rheumatism 2011 63 12 4018 4022 2-s2.0-82455210511 10.1002/art.30565
162. Reddy S., Jia S., Geoffrey R., Lorier R., Suchi M., Broeckel U., Hessner M. J., Verbsky J., An autoinflammatory disease due to homozygous deletion of the IL1RN locus. New England Journal of Medicine 2009 360 23 2438 2444 2-s2.0-66649113371 10.1056/NEJMoa0809568
163. Schnellbacher C., Ciocca G., Menendez R., Aksentijevich I., Goldbach-Mansky R., Duarte A. M., Rivas-Chacon R., Deficiency of interleukin-1 receptor antagonist responsive to Anakinra. Pediatric Dermatology 2012 2-s2.0-84859361130 10.1111/j.1525-1470.2012.01725.x
164. Brau-Javier C.N. Gonzales-Chavez J. Toro J.R. Chronic cutaneous pustulosis due to a 175-kb deletion on chromosome 2q13: Excellent response to anakinra Archives of Dermatology 2012 148 3 301-304.